⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536608 | 0.58 | — | — | |
| SCHEMBL2398119 | 0.57 | — | — | |
| SCHEMBL16551526 | 0.56 | — | — | |
| Hydrochloric Acid SCHEMBL18422639 | 0.55 | — | — | |
| SCHEMBL7102907 | 0.53 | — | — | |
| SCHEMBL31689772 | 0.52 | — | — | |
| SCHEMBL1551314 | 0.51 | — | — | |
| SCHEMBL7215917 | 0.51 | — | — | |
| Hydrochloric Acid SCHEMBL15232073 | 0.49 | — | — | |
| SCHEMBL21518866 | 0.49 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578351-B1 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-1578351-A4 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2006-06-14 | — | — | EP | disclosed |
| US-7030112-B2 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1578351-A2 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Bristol-Myers Squibb Company (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050159420-A1 | Disruption of signal transduction by inhibition of kinases in target cells | SALVATI MARK (US) | 2005-07-21 | — | — | US | disclosed |
| US-6900208-B2 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040209886-A1 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| US-20040063712-A1 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2003082208-A2 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |